SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, a precision medicine company creating therapeutics guided by the first-ever comprehensive single-cell antigen atlas for immuno-oncology targets, today announced the appointment of Chester Wong as Vice President, Head of Business Development. He is a member of Cartography’s executive leadership team.
“We are thrilled to welcome Chester to the Cartography team,” said Kevin Parker, Ph.D., Co-founder and CEO of Cartography Biosciences. “Given the broad applicability of our platform, developing key partnerships is an important aspect of our growth strategy. Chester’s deep industry experience and proven track record in establishing strategic collaborations will accelerate our ability to impact patients and drive value creation.”
“Cartography’s platform holds enormous potential for transforming the landscape of cancer immunotherapies. Our unrivaled access to tissue samples has created invaluable databases, built on cell-by-cell profiling of malignant and healthy cells, that will allow the discovery of novel antigens and deepen our understanding of known ones,” Mr. Wong said. “I look forward to leveraging the progress the company has made in advancing its platform and utilizing my experience to help Cartography realize its potential to bring therapies to patients.”
In this role, Mr. Wong will be responsible for creating key relationships that support the company’s mission and advance its pipeline of next-generation cancer immunotherapies designed around novel cell-specific targets.
He joins Cartography from Amgen, where as Director of Business Development he led the execution of several key deals across a wide range of areas including opportunities within oncology, hematology, and immunology. Previously he served on the corporate development team at Onyx Pharmaceuticals, an Amgen subsidiary, and held key roles at Astellas Pharma and Deallus Consulting. He holds a master’s degree in Bioscience from Keck Graduate Institute and a bachelor’s degree in Molecular Cell Biology from the University of California, Berkeley.
About Cartography Biosciences
Cartography Biosciences is a therapeutics company creating the first atlas to identify targets that are specific enough to only engage cancerous cells, broad enough to work across cancer cells and patients, and safe enough to sidestep toxic side effects. Founded by Kevin Parker, Howard Chang, and Ansu Satpathy, Cartography is bridging immunology and computation to understand the critical differences between normal and cancerous cells, ultimately solving the challenge of finding the safest, most selective targets for a variety of immunotherapeutic approaches. The company’s investors include 8VC, a16z, Wing VC, Catalio Capital Management, ARTIS Ventures, Alexandria Venture Investments, AME Cloud Ventures, the Cancer Research Institute, and Gaingels. To learn more about Cartography, visit cartography.bio and follow us on LinkedIn and Twitter @cartographybio.